

MARKET REPORT



Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

This Competitive Intelligence report about **Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others** evaluates as of November 26, 2016 the competitive field of mainly specific, but also bispecific new molecular entities inhibiting negative immune checkpoints, including

- **CTLA-4** (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
- **LAG-3** (Lymphocyte Activation Gene 3; CD223)
- **TIM-3** (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
- **VISTA** (V-region Ig-containing Suppressor of T-cell Activation) Receptor
- **CEACAM1** (Carcino-Embryonic Antigen Cell Adhesion Molecule 1)
- **BTLA** (B- and T-Lymphocyte Attenuator)
- **GARP** (Glycoprotein A Repetitions Predominant)
- **TIGIT** (T-cell Immunoreceptor with Ig and ITIM domains)
- **IL-10** (Interleukin-10)
- **B7-H3** (CD276)

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

More than 10 antibodies inhibiting negative immune checkpoints are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further five molecules are undergoing IND-enabling studies.

The report includes a compilation of currently active projects in research and development of immune checkpoint inhibitors. In addition, the report lists company-specific R&D pipelines of Immune Checkpoint Inhibitors. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Additional Details

Publisher : La Merie

Reference : LMCA0158

Number of Pages : 74

Report Format : PDF

Publisher Information :



La:Merie
Publishing

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Table Of Contents for Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Table of Contents

1) CTLA-4 Antagonists

- Yervoy (ipilimumab) monotherapy
- Yervoy (ipilimumab) combination with Opdivo (nivolumab)
- Yervoy (ipilimumab) combination with other therapeutics
- Tremelimumab monotherapy
- Tremelimumab combination with durvalumab
- Tremelimumab combination with other therapeutics
- Novel Specific CTLA-4 Antagonists
- Novel Bispecific CTLA-4 Antagonists

2) LAG-3 Antagonists

3) TIM-3 Antagonists

4) Inhibitors of Other Negative Immune Checkpoints

5) Corporate Immune Checkpoint Inhibitor R&D Pipelines

How to Buy...

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/31942>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$550** | Single User Price
- \$1100** | Site License Price
- \$1650** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.